Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RUBY SHARMA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1750589701
CMS profile
306339
Location
NEW HYDE PARK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$197.74

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $197.74 2

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Daiichi Sankyo Inc. $197.74 2

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RUBY SHARMA

NPI 1750589701 · CMS profile ID 306339

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

NEW HYDE PARK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750589701?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RUBY SHARMA, NPI 1750589701, CMS profile ID 306339. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750589701?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). RUBY SHARMA, NPI 1750589701, CMS profile ID 306339. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750589701?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
RUBY SHARMA, NPI 1750589701, CMS profile ID 306339, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1750589701?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $197.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Daiichi Sankyo Inc. $98.8709/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197028815 CMS
Daiichi Sankyo Inc. $98.8704/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197039079 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $11.92 1
PY2025 $197.74 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $224,659.08 33
PY2024 Recipient $3,980.45 2
PY2024 Principal investigator $163,750.12 115
PY2023 Principal investigator $34,087.45 25
PY2022 Principal investigator $78,816.63 15
PY2021 Principal investigator $30,541.64 13
PY2020 Principal investigator $72,053.68 14
PY2019 Principal investigator $109,431.78 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

117 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca UK Limited $34.88 12/31/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib Fulvestrant Versus Placebo Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor (CAPItello-291) No dispute reported 06/30/2026 1155804910
Principal investigator 1 PFIZER INC. $500.00 11/21/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1130919335
Principal investigator 1 PFIZER INC. $54.70 11/21/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1130919737
Principal investigator 1 PFIZER INC. $500.00 11/21/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1130920307
Principal investigator 1 PFIZER INC. $500.00 09/26/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1130919395
Principal investigator 1 PFIZER INC. $500.00 09/26/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1130919741
Principal investigator 1 PFIZER INC. $500.00 09/26/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1130920020
Principal investigator 1 PFIZER INC. $500.00 09/26/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1130920315
Recipient Eli Lilly and Company $3,946.00 09/24/2024 Covered Recipient Physician EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1137348375
Principal investigator 1 Eli Lilly and Company $33,810.00 09/17/2024 Non-covered Recipient Entity
FEINSTEIN INSTITUTE FOR MEDICAL
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1137359147
Recipient Eli Lilly and Company $34.45 08/23/2024 Covered Recipient Physician EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1137349203
Principal investigator 1 PFIZER INC. $10,000.00 08/21/2024 Non-covered Recipient Entity
Feinstein Institute for Medical Research
THE COMPASSHER2 TRIALS COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2POSITIVE BREAST CANCER COMPASSHER2 RESIDUAL DISEASE RD A DOUBLEBLINDED PHASE III RANDOMIZED TRIAL OF TDM1 COMPARED WITH TDM1 AND TUCATINIB No dispute reported 06/30/2026 1130920271
Principal investigator 1 Hoffmann-La Roche Limited $1,057.50 07/22/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE of NY LLC
A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY No dispute reported 06/30/2026 1133384103
Principal investigator 1 PFIZER INC. $54.70 07/17/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1130919339
Principal investigator 1 PFIZER INC. $500.00 07/17/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1130919343
Principal investigator 1 PFIZER INC. $54.70 07/17/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1130919399
Principal investigator 1 PFIZER INC. $54.70 07/17/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1130919745
Principal investigator 1 PFIZER INC. $500.00 07/17/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1130919801
Principal investigator 1 PFIZER INC. $54.70 07/17/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1130919805
Principal investigator 1 PFIZER INC. $500.00 07/17/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1130919809
Principal investigator 1 PFIZER INC. $500.00 07/17/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1130919860
Principal investigator 1 PFIZER INC. $500.00 07/17/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1130919864
Principal investigator 1 PFIZER INC. $500.00 07/17/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1130920016
Principal investigator 1 PFIZER INC. $500.00 07/17/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1130920311
Principal investigator 1 Hoffmann-La Roche Limited $6,800.00 06/21/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE of NY LLC
A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY No dispute reported 06/30/2026 1133384095
Principal investigator 1 PFIZER INC. $54.70 04/26/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131036718
Principal investigator 1 PFIZER INC. $54.70 04/26/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131036927
Principal investigator 1 PFIZER INC. $500.00 04/26/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131037424
Principal investigator 1 PFIZER INC. $500.00 04/26/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038599
Principal investigator 1 Hoffmann-La Roche Limited $130.00 03/26/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE of NY LLC
A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY No dispute reported 06/30/2026 1133384093
Principal investigator 1 Hoffmann-La Roche Limited $1,050.00 03/26/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE of NY LLC
A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY No dispute reported 06/30/2026 1133384101
Principal investigator 1 PFIZER INC. $500.00 03/18/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131037252
Principal investigator 1 PFIZER INC. $500.00 03/18/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131037962
Principal investigator 1 PFIZER INC. $500.00 03/18/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038268
Principal investigator 1 PFIZER INC. $500.00 03/18/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038291
Principal investigator 1 Hoffmann-La Roche Limited $2,350.00 03/17/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE of NY LLC
A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY No dispute reported 06/30/2026 1133384097
Principal investigator 1 Eli Lilly and Company $4,341.86 03/08/2024 Covered Recipient Teaching Hospital
STATEN ISLAND UNIVERSITY HOSPITAL
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1137350159
Principal investigator 1 Eli Lilly and Company $2,170.93 03/08/2024 Covered Recipient Teaching Hospital
PHELPS MEMORIAL HOSPITAL CENTER
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1137351592
Principal investigator 1 Eli Lilly and Company $2,170.93 03/08/2024 Non-covered Recipient Entity
NORTHERN WESTCHESTER HOSPITAL
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1137364767
Principal investigator 1 Eli Lilly and Company $2,665.08 03/08/2024 Non-covered Recipient Entity
QUEENS MEDICAL ASSOCIATES
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1137364807
Principal investigator 1 Hoffmann-La Roche Limited $1,000.00 03/05/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE of NY LLC
A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY No dispute reported 06/30/2026 1133384099
Principal investigator 1 AstraZeneca UK Limited $33,040.51 02/23/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib Fulvestrant Versus Placebo Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor (CAPItello-291) No dispute reported 06/30/2026 1110843388
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131036308
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131036314
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131036320
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131036706
Principal investigator 1 PFIZER INC. $500.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131036713
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131036918
Principal investigator 1 PFIZER INC. $1,000.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131036923
Principal investigator 1 PFIZER INC. $1,000.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131037246
Principal investigator 1 PFIZER INC. $500.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131037258
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131037418
Principal investigator 1 PFIZER INC. $500.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131037591
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131037595
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131037598
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131037602
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131037748
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131037754
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131037760
Principal investigator 1 PFIZER INC. $2,030.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131037766
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131037772
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131037915
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131037921
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131037927
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131037933
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131037939
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131037944
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131037950
Principal investigator 1 PFIZER INC. $500.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131037956
Principal investigator 1 PFIZER INC. $500.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038121
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038127
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038132
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038138
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038274
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038279
Principal investigator 1 PFIZER INC. $500.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038285
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038297
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038303
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038309
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038314
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038480
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038486
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038492
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038498
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038504
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038509
Principal investigator 1 PFIZER INC. $500.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038515
Principal investigator 1 PFIZER INC. $1,000.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038569
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038575
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038581
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038592
Principal investigator 1 PFIZER INC. $500.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038605
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038792
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038798
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038804
Principal investigator 1 PFIZER INC. $500.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038815
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038821
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038827
Principal investigator 1 PFIZER INC. $500.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038833
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038838
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038937
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038942
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131038948
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131039117
Principal investigator 1 PFIZER INC. $1,000.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131039123
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131039129
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131039135
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131039140
Principal investigator 1 PFIZER INC. $500.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131039146
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131039348
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131039353
Principal investigator 1 PFIZER INC. $500.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131039359
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131039519
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131039525
Principal investigator 1 PFIZER INC. $600.00 02/15/2024 Non-covered Recipient Entity
The Feinstein Institute for Medical Research
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER No dispute reported 06/30/2026 1131039531
Principal investigator 1 Hoffmann-La Roche Limited $4,760.00 01/23/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY No dispute reported 06/30/2026 1133384045
Principal investigator 1 Eli Lilly and Company $2,855.53 01/09/2024 Non-covered Recipient Entity
NORTHWELL HEALTH-CNTR ADVN MED
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1137363223